Anna Mae Diehl

68.4k total citations · 25 hit papers
407 papers, 51.5k citations indexed

About

Anna Mae Diehl is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Anna Mae Diehl has authored 407 papers receiving a total of 51.5k indexed citations (citations by other indexed papers that have themselves been cited), including 268 papers in Epidemiology, 166 papers in Hepatology and 121 papers in Molecular Biology. Recurrent topics in Anna Mae Diehl's work include Liver Disease Diagnosis and Treatment (256 papers), Liver physiology and pathology (104 papers) and Diet, Metabolism, and Disease (77 papers). Anna Mae Diehl is often cited by papers focused on Liver Disease Diagnosis and Treatment (256 papers), Liver physiology and pathology (104 papers) and Diet, Metabolism, and Disease (77 papers). Anna Mae Diehl collaborates with scholars based in United States, United Kingdom and Portugal. Anna Mae Diehl's co-authors include Jeanne M. Clark, Elizabeth M. Brunt, Joel E. Lavine, Arun J. Sanyal, Steve S. Choi, Naga Chalasani, Mariana Verdelho Machado, Manal F. Abdelmalek, Zobair M. Younossi and Frederick L. Brancati and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Anna Mae Diehl

401 papers receiving 50.3k citations

Hit Papers

The diagnosis and management of... 1988 2026 2000 2013 2012 2010 2014 2012 2015 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
    2012 3.0k citations Naga Chalasani, Joel E. Lavine et al. Hepatology profile →
  2. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
    2010 2.5k citations Arun J. Sanyal, Naga Chalasani et al. profile →
  3. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
    2014 1.7k citations Brent A. Neuschwander‐Tetri, Rohit Loomba et al. profile →
  4. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
    2012 1.4k citations Naga Chalasani, Joel E. Lavine et al. profile →
  5. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota
    2015 1.1k citations Cynthia D. Guy, Lawrence A. David et al. Hepatology profile →
  6. The Prevalence and Etiology of Elevated Aminotransferase Levels in The United States
    2003 1.1k citations Anna Mae Diehl et al. profile →
  7. Leptin regulates proinflammatory immune responses
    1998 986 citations Anna Mae Diehl et al. profile →
  8. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
    2017 909 citations Anna Mae Diehl et al. profile →
  9. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
    2007 805 citations Anna Mae Diehl et al. Hepatology profile →
  10. NAFLD, NASH and liver cancer
    2013 768 citations Gregory Michelotti, Anna Mae Diehl et al. profile →
  11. Nonalcoholic fatty liver disease
    2002 766 citations Anna Mae Diehl et al. profile →
  12. Cytokines in Alcoholic and Nonalcoholic Steatohepatitis
    2000 765 citations Herbert Tilg, Anna Mae Diehl profile →
  13. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease
    2003 758 citations Anna Mae Diehl et al. Hepatology profile →
  14. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis
    1997 675 citations Anna Mae Diehl et al. profile →
  15. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
    2018 668 citations Manal F. Abdelmalek, Anna Mae Diehl et al. Journal of Hepatology profile →
  16. Fructose consumption as a risk factor for non-alcoholic fatty liver disease
    2008 637 citations Anna Mae Diehl, Manal F. Abdelmalek et al. Journal of Hepatology profile →
  17. Increased Fructose Consumption Is Associated With Fibrosis Severity in Patients With Nonalcoholic Fatty Liver Disease
    2010 581 citations Manal F. Abdelmalek, Ayako Suzuki et al. Hepatology profile →
  18. Metformin reverses fatty liver disease in obese, leptin-deficient mice
    2000 564 citations Anna Mae Diehl et al. profile →
  19. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
    2017 435 citations Rohit Loomba, Anna Mae Diehl et al. Hepatology profile →
  20. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
    2012 429 citations Naga Chalasani, Joel E. Lavine et al. profile →
  21. Pathogenesis of Nonalcoholic Steatohepatitis
    2016 401 citations Anna Mae Diehl et al. profile →
  22. Alcohollike liver disease in nonalcoholics
    1988 382 citations Anna Mae Diehl et al. profile →
  23. Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease
    2015 292 citations Gregory Michelotti, Guanhua Xie et al. PLoS ONE profile →
  24. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
    2019 270 citations Laura Wilson, Cynthia D. Guy et al. profile →
  25. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
    2019 255 citations Arun J. Sanyal, Manal F. Abdelmalek et al. Hepatology profile →

Peers

Anna Mae Diehl
Elizabeth M. Brunt United States
Rohit Loomba United States
Arthur J. McCullough United States
David A. Brenner United States
Herbert Tilg Austria
Ariel E. Feldstein United States
Bin Gao United States
Michael Trauner Austria
Ramón Bataller Spain
Hannele Yki‐Järvinen Finland
Elizabeth M. Brunt United States
Anna Mae Diehl
Citations per year, relative to Anna Mae Diehl Anna Mae Diehl (= 1×) peers Elizabeth M. Brunt

Countries citing papers authored by Anna Mae Diehl

Since Specialization
Citations

This map shows the geographic impact of Anna Mae Diehl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Mae Diehl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Mae Diehl more than expected).

Fields of papers citing papers by Anna Mae Diehl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Mae Diehl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Mae Diehl. The network helps show where Anna Mae Diehl may publish in the future.

Co-authorship network of co-authors of Anna Mae Diehl

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Mae Diehl. A scholar is included among the top collaborators of Anna Mae Diehl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Mae Diehl. Anna Mae Diehl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Du, Kuo, David S. Umbaugh, Nanqi Ren, & Anna Mae Diehl. (2025). Cellular senescence in liver diseases: From molecular drivers to therapeutic targeting. Journal of Hepatology. 84(1). 194–212. 1 indexed citations
2.
Umbaugh, David S., Anna Mae Diehl, & Kuo Du. (2025). Redefining senescence through hepatocyte fate changes in liver diseases. Trends in Endocrinology and Metabolism. 2 indexed citations
3.
Barzi, Mercedes, Tong Chen, Yunhan Ma, et al.. (2024). A humanized mouse model for adeno-associated viral gene therapy. Nature Communications. 15(1). 1955–1955. 7 indexed citations
4.
Du, Kuo, Liuyang Wang, Ji Hye Jun, et al.. (2024). Aging promotes metabolic dysfunction-associated steatotic liver disease by inducing ferroptotic stress. Nature Aging. 4(7). 949–968. 31 indexed citations
5.
Chalasani, Naga, Eduardo Vilar‐Gómez, Rohit Loomba, et al.. (2024). PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. Hepatology. 80(5). 1212–1226. 18 indexed citations
6.
Murphy, William A., Anna Mae Diehl, Matthew Shane Loop, et al.. (2024). Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD. Hepatology Communications. 8(3). 7 indexed citations
7.
Maeso‐Díaz, Raquel, Kuo Du, Christopher C. Pan, et al.. (2023). Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression. Hepatology. 78(4). 1209–1222. 19 indexed citations
8.
Wegermann, Kara, Marat Fudim, Ricardo Henao, et al.. (2023). Serum Metabolites Are Associated With HFpEF in Biopsy‐Proven Nonalcoholic Fatty Liver Disease. Journal of the American Heart Association. 12(14). e029873–e029873. 5 indexed citations
9.
Du, Kuo, Raquel Maeso‐Díaz, Ergang Wang, et al.. (2023). Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis. Hepatology. 77(6). 1998–2015. 60 indexed citations
10.
Zhou, Jin, Madhulika Tripathi, Jia Pei Ho, et al.. (2022). Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression. Nature Communications. 13(1). 5202–5202. 55 indexed citations
11.
Ramalingam, Sendhilnathan, Mohammad Rauf Chaudhry, Yi Ren, et al.. (2020). Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. PLoS ONE. 15(9). e0238824–e0238824. 4 indexed citations
12.
Diehl, Anna Mae, Nathalie J. Farpour‐Lambert, Liping Zhao, & Herbert Tilg. (2019). Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease. Nature Metabolism. 1(11). 1027–1029. 18 indexed citations
13.
Reese, Aspen T., Fátima C. Pereira, Arno Schintlmeister, et al.. (2018). Microbial nitrogen limitation in the mammalian large intestine. Nature Microbiology. 3(12). 1441–1450. 92 indexed citations
14.
Zhu, Changyu, KyeongJin Kim, Xiaobo Wang, et al.. (2018). Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Science Translational Medicine. 10(468). 194 indexed citations
15.
Kim, Jieun, Jeongeun Hyun, Sihyung Wang, et al.. (2017). Thymosin beta-4 regulates activation of hepatic stellate cells via hedgehog signaling. Scientific Reports. 7(1). 3815–3815. 22 indexed citations
16.
Markowitz, Geoffrey J., Pengyuan Yang, Jing Fu, et al.. (2016). Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes. Cancer Research. 76(8). 2394–2405. 42 indexed citations
17.
Chan, Isaac S., Cynthia D. Guy, Yuping Chen, et al.. (2012). Paracrine Hedgehog Signaling Drives Metabolic Changes in Hepatocellular Carcinoma. Cancer Research. 72(24). 6344–6350. 41 indexed citations
18.
Xie, Guanhua, Steve S. Choi, Wing‐Kin Syn, et al.. (2012). Hedgehog signalling regulates liver sinusoidal endothelial cell capillarisation. Gut. 62(2). 299–309. 103 indexed citations
19.
Arzumanyan, Alla, Vaishnavi Sambandam, Marcia M. Clayton, et al.. (2012). Hedgehog Signaling Blockade Delays Hepatocarcinogenesis Induced by Hepatitis B Virus X Protein. Cancer Research. 72(22). 5912–5920. 58 indexed citations
20.
Sun, Zhaoli, Xiuying Zhang, Jayme E. Locke, et al.. (2008). Recruitment of host progenitor cells in rat liver transplants #. Hepatology. 49(2). 587–597. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth M. Brunt Breakdown of academic impact, for papers by Rohit Loomba Breakdown of academic impact, for papers by Arthur J. McCullough Breakdown of academic impact, for papers by David A. Brenner Breakdown of academic impact, for papers by Herbert Tilg Breakdown of academic impact, for papers by Ariel E. Feldstein Breakdown of academic impact, for papers by Bin Gao Breakdown of academic impact, for papers by Michael Trauner Breakdown of academic impact, for papers by Ramón Bataller Breakdown of academic impact, for papers by Hannele Yki‐Järvinen
Rankless by CCL
2026